enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. List of antileukemic drugs - Wikipedia

   en.wikipedia.org/wiki/List_of_antileukemic_drugs

   Antileukemic drugs, anticancer drugs that are used to treat one or more types of leukemia, include: [1] 6-Mercaptopurine; 6-Thioguanine; Arsenic trioxide; Asparaginase;

3. Venetoclax - Wikipedia

   en.wikipedia.org/wiki/Venetoclax

   Venetoclax is also indicated as part of a combination therapy for acute myeloid leukemia (AML). [7] For this purpose it is used with azacitidine, decitabine, or low-dose cytarabine for newly diagnosed adults who are age 75 years or older, or those with other health problems where intensive chemotherapy cannot be used.

4. List of therapeutic monoclonal antibodies - Wikipedia

   en.wikipedia.org/wiki/List_of_therapeutic...

   B-cell Hodgkin's lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia Camrelizumab [22] mab: humanized: PD-1: hepatocellular carcinoma: Canakinumab [43] Ilaris: mab: human: IL-1: Y: cryopyrin-associated periodic syndrome, Yao's Syndrome, Adult Onset Still's Disease: Cantuzumab mertansine [42] mab: humanized ...

5. 'How are you supposed to live?' Some cancer patients skip ...

   www.aol.com/supposed-live-cancer-patients-skip...

   For premium support please call: 800-290-4726 more ways to reach us

6. Imatinib - Wikipedia

   en.wikipedia.org/wiki/Imatinib

   In many cases, Imatinib can induce a complete cytogenetic response (CCyR) and major molecular response (MMR) and many patients can have a long-term remission. It is also used to maintain remission in chronic phase CML patients. While Imatinib is a very effective treatment for CML and some types of ALL, it is not a cure for leukemia.

7. Ponatinib - Wikipedia

   en.wikipedia.org/wiki/Ponatinib

   As of 2015, ponatinib is available in England for the treatment of chronic myeloid leukemia (chronic phase, accelerated phase or blast phase) and Philadelphia-positive acute lymphoblastic leukemia in patients with documented T315I mutation under the Cancer Drugs Fund, [19] and has not been appraised by the National Institute for Health and Care ...